Aims: Fingolimod, an orally active immunomodulatory drug for relapsing-remitting multiple sclerosis (RRMS), sequesters T cells in lymph nodes through functional antagonism of the sphingosine-1-phosphate receptor, reducing the number of potential autoreactive cells that migrate to the central nervous system. However, not all RRMS patients respond to this therapy. Our aim was to test the hypothesis that by immunemonitoring RRMS patient's leukocyte subpopulations it is possible to find biomarkers associated with clinical response to fingolimod.
| INTRODUC TI ON
Fingolimod is an immune-modulatory treatment for relapsingremitting multiple sclerosis (RRMS) patients, reducing significantly disease activity. 1, 2 This drug embodies and degrades the sphingosine-1-phosphate (S1P) receptor on leukocytes, inhibiting the egress of lymphocytes from lymph nodes. Fingolimod acts specifically on cells expressing CCR7 on their surface, which is the main chemokine receptor involved in homing to lymph nodes.
3,4
This molecule is mainly expressed by naïve and central memory T and B cells. Hence, effector memory cells, which lack CCR7, remain unaffected. 5 Patients under fingolimod treatment present peripheral blood lymphopenia due to the redistribution of leukocytes, which are being trapped inside lymph nodes. Consequently, this treatment reduces the migration of potential inflammatory cells to the central nervous system. Its use in Europe has been restricted to highly active RRMS patients or as escalation after failure to first-line disease modifying therapies (DMT). 6 Previous studies by
Cohen et al 1 found that 83% of patients under fingolimod treatment remain relapse free after the first year, and Kappos et al 2 a
70, 4% after 2 years of follow-up. However, failure mechanisms or suboptimal response to fingolimod were not addressed in those studies.
In a preliminary longitudinal study, we showed that a higher percentage of recent thymic emigrants (RTE) and transitional B cells at baseline correlate with a suboptimal response to fingolimod, 7 sug- 
| ME THODS

| Patients
A total of 44 RRMS patients under fingolimod treatment from 5 distinct MS units in Catalonia (Spain) and who were selected according to McDonald's criteria 2010 8 were included. Patients were monitored for 12 months. This cohort is an extension of our pilot study.
7
The study protocol was approved by the local ethics committees of the participating centers, and the patients signed the informed consent prior to their inclusion in the study.
Eligible MS patients were aged between 18 and 59 and had Expanded Disability Status Scale (EDSS) scores ≤6.0. Noneligible patients either had progressive forms of MS or were receiving interferon beta (IFNβ) or glatiramer acetate (GA) within at least the previous 24 hours or natalizumab (NTZ) or metilprednisolone within the previous 30 days.
The cohort was monitored for 12 months.
During follow-up, immunological and clinical parameters (adverse events, relapses, and EDSS score) were recorded at baseline, +1, +3, +6, and +12 months after starting the treatment.
A relapse of MS was defined as occurrence, recurrence, or worsening of symptoms of neurological dysfunction lasting over 24 hours without infection or fever. The annualized relapse rate (ARR) was defined as the total number of relapses divided by the number of patients/y. The ARR was assessed in the 12 months prior to the initiation of treatment (baseline), and after 12-month follow-up.
Disability progression was defined as an increase of at least 1 point in the EDSS score sustained over at least 6 months.
Brain magnetic resonance imaging (MRI) scans were performed at baseline and at +12 months and the number of new/enlarged lesions on T2-weighted MRI recorder for all patients. Both brain MRI scans of each patient were carried out with the same equipment.
Additionally, MRI with gadolinium (Gd) administration was performed in 22 patients and gadolinium-enhancing (Gd+) T1 lesions recorded.
Patients were divided into those with good response to treatment (R) or those with suboptimal response to treatment (NR) according to the Rio Score 9 : A patient was considered a NR patient when at least 2 of the following 3 criteria were met: (i) 1 or more clinical relapse(s) during the first 12 months of treatment, (ii) an increase of at least 1 point in the EDSS score sustained over at least 6 months, and (iii) the presence at month +12 of active lesions in brain MRI (ie, >2 new or enlarging T2-weighted lesions or at least 1 Gd-enhancing T1-weighted lesion).
| Flow cytometry analysis
Peripheral blood samples were collected in ethylene diamine tetra acetic acid (EDTA) at baseline and at +1, +3, +6, and +12 months of treatment. Analysis of leukocyte subpopulations was evaluated in patients with at least 6 months of follow-up.
Samples of whole blood were incubated with monoclonal antibodies for 20 minutes at room temperature and in darkness.
Samples were washed and acquired on LSRFortessa flow cytometer (BD Biosciences, San José, CA, USA) after erythrocyte lysis.
Leukocyte subpopulations were defined over 4 panels using the markers specified in Table 1 The gating strategy to analyze the desired leukocyte subpopulations ( Figures S1-S4 ) was based on international consensus.
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Recent thymic emigrants subpopulation analysis and absolute cell number quantification were performed as previously reported. 
| Statistical analysis
| RE SULTS
| Patients
Forty-four RRMS patients were selected for the study, but 4 of them were not eligible for further analysis due to atrioventricular (AV) block after the first dose of fingolimod (2 patients) or recurrent infections during the first 3 months of follow-up (2 patients).
Additionally, before the end of the study 6 patients discontinued treatment due to a pregnancy wish (1 patient), hepatotoxicity
(1 patient), lymphopenia (1 patient), unclassified (1 patient), or lack of effectiveness (2 patients). Nonetheless, the latter 2 patients were classified as NR complying with our response criteria. As a result, a total of 36 patients were analyzed in relation to clinical response: R (28 patients) and NR (8 patients). There were no differences in gender, age, disease duration, previous immunomodulatory treatments, (Table 2) .
Regarding the previous MS treatment, patients were classified as naïve (n = 15) and patients who had received previous treatment,
, or Extavia ® (injectable drugs) (n = 12), or (ii) NTZ, who had stopped due to risk of progressive multifocal leukoencephalopathy (n = 9). The demographic and clinical characteristics of patients analyzed are shown in Table 2 .
| Treatment efficacy
The ARR was significantly reduced during the follow-up compared to the 12 months prior to fingolimod treatment (0.6 ± 0.8 vs 1.6 ± 1.2, P < 0.001). The distribution of patients depending on the previous treatment showed a reduction in ARR of injectable drugs (from 1.5 ± 1.4 to 0.5 ± 0.7; P < 0.01) and naïve patients (from 1.7 ± 1.1 to 0.9 ± 0.9; P < 0.05). However, in patients who had received NTZ, the ARR remained unchanged during fingolimod treatment (from 0.6 ± 0.9 to 0.7 ± 1.1; P = 0.625). A significant reduction in the ARR was also observed when patients were stratified according to the clinical response. R patients showed 0.4 ± 0.7 ARR compared to the 12 months prior to fingolimod treatment (1.6 ± 1.5) (P < 0.001).
No significant reduction in the ARR was observed for NR (P = 0.73) (Table 3) . NR group only included 1 patient with previous NTZ treatment (Table 3) .
No statistically significant differences were observed in EDSS score after 12 months of treatment in the R and NR group (P = 0.77; P = 0.6; respectively) ( Table 3) .
The proportion of patients free of new/enlarged T2 lesions in R patients was 52% and in NR patients was 13% at month 12. A total of 8 patients had new Gd+ T1 lesions at month +12 (24% of R patients and 80% of NR patients) ( Table 3 ).
| Adverse effects
Fingolimod treatment caused at least 1 adverse effect during the follow-up in 35 patients (80%) ( Table 4) . Most of the adverse effects were considered mild or moderate in severity.
A total of 29 patients (66%) presented lymphopenia, being counts ≤200 lymphocytes/μL in 5 of them ( TA B L E 2 Demographic and clinical characteristics of the patients before fingolimod treatment (n = 36)
| Fingolimod treatment affects mainly T and B lymphocytes
Total lymphocyte counts were drastically reduced after the (Tables S1 and S2 ). decreased compared with baseline data from patients under fingolimod treatment ( Figure 1A ,B) (Table S1 ). These changes were already present at the first month of treatment (P < 0.001). When analyzing the number of cells, Th1 EM remained unchanged until month +12 of treatment (Table S3) Table S1 ).
Th1Th17 lymphocytes-another Th subset not formerly studied in patients under fingolimod treatment-were analyzed too. ) percentages were decreased progressively, being these differences statistically significant from month +3 until the end of follow-up (P < 0.01) ( Figure 1E ,F and Table S1 ). (Figure 1H ), from month +1 until the end of follow-up (P < 0.001) (Tables S1 and S2 ).
| Baseline differences in lymphocyte subpopulations in fingolimod R patients
After analyzing data from 36 RRMS patients to find correlation be- 36.1 ± 8.8% vs NR: 27.2 ± 5.2%, P = 0.013) ( Figure 2C ) similarly to our preliminary study.
7
This study revealed also differences in other lymphocyte subpopulations at baseline between R and NR patients. R patients showed 
| D ISCUSS I ON
Clinical heterogeneous response to different treatments exists in MS patients, 11 possibly partially due to the heterogeneity of MS pathology. This is why an exhaustive analysis of the immunological background of the patients and knowledge on their ability to respond to different therapeutic alternatives is still needed. [12] [13] [14] [15] [16] We examined in the present study changes in leukocyte subpopulations and their association with clinical and brain MRI activity in RRMS patients before and during 1 year of follow-up under fingolimod treatment. Our analysis revealed lymphocyte subpopulations that can be used as biomarkers to predict the clinical response to fingolimod at baseline, even before starting treatment. From these biomarkers, the percentage of RTE was the best parameter to differentiate R and NR patients. Some research groups have described changes in peripheral blood subpopulations from MS patients caused by fingolimod treatment. [17] [18] [19] [20] [21] [22] [23] [24] Due to S1P receptor being blocked in the surface of lymphocytes, fingolimod triggers the lymphocytes to be confined in lymph nodes and induces a peripheral lymphopenia, affecting mainly naïve and central memory, but not effector memory cells. Data collected from their studies support the idea that the beneficial effect of fingolimod may be due to an increase in regulatory T cells (T reg ) and/or a decrease in Th17 cells in peripheral blood. 17, 20, 24 In our longitudinal study, we observed major changes In the past years, it was quite difficult to compare results from studies analyzing RTE due to the lack of specific markers for this immature stage of T cells. Recently, PTK7 (protein tyrosine kinase 7)
was identified and reported as the best surrogate marker of RTE.
27
PTK 7 + cells are CD31 + and have high levels of signal joint TCR gene excision circles (sjTREC), the most frequently used molecular marker to define RTE lymphocytes.
When the age of healthy donors was taken into account, a decrease in the percentage of RTE was reported, probably due to a less effective thymopoiesis. 28 Importantly, while using the same markers, R and NR patients in our study did not show any differences related to age, excluding it from being the cause of differences found in the percentages of RTE. The influence of previous NTZ treatment on the baseline levels of RTE remains to be clarified. Our group found in a previous work that NTZ stimulates the release of hematopoietic precursors and that patient under NTZ treatment shows an increase in RTE and transitional B cells. 29 In the present study, we analyzed differences in RTE percentage at baseline between naïve and treated patients (either with injectable drugs or with NTZ), to discard a possible influence of former treatments on RTE baseline levels. Remarkably, the NR group only included 1 patient who was previously treated with NTZ, and it had a washout period of 5 months, discarding in this way influence of former NTZ treatment on higher levels of RTE found in the NR.
The main limitation of this study is the small cohort of noresponders with different treatment histories and washout periods.
In order to use this biomarker in clinical practice-alone or in combination with others-analysis of a large cohort of patients is required to define the optimal RTE threshold able to discriminate between R and NR.
In conclusion, the results of this study strongly suggest that RRMS patients can be stratified in R and NR to fingolimod before starting the treatment. We found the RTE percentage as the best . Each dot represents the value of an individual patient. *P < 0.05; **P < 0.01; ***P < 0.001 treatment MS patients will respond or not and will be a big step toward personalizing medicine in MS. 
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